STRAKE INC. VITANA-X INC. AND SUBSIDIARY
CONSOLIDATED INTERIM FINANCIAL STATEMENTS
Nine months ended April 30, 2022 and 2021
(Unaudited)
VITANA-X INC. AND SUBSIDIARY
CONSOLIDATED INTERIM FINANCIAL STATEMENTS
Nine months ended April 30, 2022 and 2021
(Unaudited)
CONTENTS | |
Consolidated Interim Balance Sheets | 3 |
Consolidated Interim Statement of Operations | 4 |
Consolidated Interim Statement of Changes in Shareholders' Equity (Deficit) | 5 |
Consolidated Interim Statement of Cash Flows | 7 |
Notes to the Consolidated Interim Financial Statements | 8 |
2
VITANA-X INC. AND SUBSIDIARY
CONSOLIDATED INTERIM BALANCE SHEETS
Nine months ended April 30, 2022 and 2021
(Unaudited)
April 30, | July 31, | ||||
in USD | Notes | 2022 | 2021 | ||
ASSETS | |||||
CURRENT ASSETS | |||||
Cash and cash equivalents | 10,407 | 23,035 | |||
Receivables due from credit card processor | - | 40,019 | |||
Inventory | - | 434,250 | |||
Other current receivables due from related parties | - | 74,553 | |||
Other current assets | 167 | 36,702 | |||
TOTAL CURRENT ASSETS | 10,574 | 608,559 | |||
NON-CURRENT ASSETS | |||||
Fixed assets (net of depreciation) | - | 40,525 | |||
Intangible assets (net of amortization) | - | 170,799 | |||
TOTAL NON-CURRENT ASSETS | - | 211,324 | |||
TOTAL ASSETS | 10,574 | 819,883 | |||
LIABILITIES AND STOCKHOLDERS' DEFICIT | |||||
CURRENT LIABILITIES | |||||
Accounts payable | 123,879 | 342,001 | |||
Financial liabilities | 4 | - | 191,252 | ||
Provisions | - | 224,563 | |||
Other current liabilities | 69,252 | 157,739 | |||
TOTAL CURRENT LIABILITIES | 193,131 | 915,555 | |||
NON-CURRENT LIABILITIES | |||||
Financial liabilities | 4 | - | 135,224 | ||
Financial liabilities due to directors | 4 | - | - | ||
Financial liabilities - Convertible notes payable | 4 | 91,568 | 297,473 | ||
TOTAL NON-CURRENT LIABILITIES | 91,568 | 432,697 | |||
TOTAL LIABILITIES | 284,699 | 1,348,252 |
STOCKHOLDERS' DEFICIENCY
Series A Preferred Stock; $0.0001 par value; 1,000,000 designated; 1,000,000 shares issued (July 31, 2021: NIL)
Series B Preferred Stock; $0.0001 par value; 1,344,756 shares designated; NIL shares issued (July 31, 2021: 1,344,756 )
Common Stock; $0.0001 par value; 5,000,000,000 shares authorized; 3,324,585,062 shares issued (July 31, 2021: 1,366,002,045) Additional paid-in capital
Reserve for unissued shares
Treasury Stock
Cumulative translation adjustment
Accumulated deficit
5.3 | 100 | - | |||||
5.4 | |||||||
- | 134 | ||||||
5.1 | |||||||
324,559 | 136,600 | ||||||
4,882,053 | 2,185,778 | ||||||
42,902 | 2,166,314 | ||||||
8 | (257,600) | - | |||||
- | (5,906) | ||||||
(5,266,139) | (5,011,289) |
TOTAL STOCKHOLDERS' DEFICIT | (274,125) | (528,369) | |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | 10,574 | 819,883 |
See accompanying notes to the consolidated interim financial statements (unaudited).
3
VITANA-X INC. AND SUBSIDIARY
CONSOLIDATED INTERIM STATEMENT OF OPERATIONS
Nine months ended April 30, 2022 and 2021
(Unaudited)
Three months ended | Nine months ended | ||||||||
April 30, | April 30, | ||||||||
in USD | Notes | 2022 | 2021 | 2022 | 2021 | ||||
Revenues | 47,843 | 433,481 | 497,064 | 846,811 | |||||
Cost of goods sold | (14,943) | (198,758) | (358,250) | (362,719) | |||||
Gross profit | 32,900 | 234,723 | 138,814 | 484,092 | |||||
Operating expenses | |||||||||
General and administrative | 50,238 | 318,704 | 528,790 | 379,848 | |||||
Depreciation and amortization | (1) | 662 | 173,014 | 890 | |||||
Professional fees | 141,310 | 741,530 | 521,561 | 1,601,525 | |||||
Total operating expenses | 191,547 | 1,060,896 | 1,223,365 | 1,982,263 | |||||
LOSS FROM OPERATIONS | (158,647) | (826,173) | (1,084,551) | (1,498,171) | |||||
Other income (expenses) | |||||||||
Fair value changes of derivative financial instruments | - | - | - | 255,399 | |||||
Gain (loss) from foreign currency transactions | 478 | - | 24,830 | - | |||||
Other financial expenses | (1,215) | 19,690 | (9,560) | 13,417 | |||||
Total Other Income (Expenses) | (737) | 19,690 | 15,270 | 268,816 | |||||
NET LOSS | (159,384) | (806,483) | (1,069,281) | (1,229,355) | |||||
NET LOSS PER COMMON SHARE | 6 | ||||||||
Basic and diluted | (0.00) | (0.00) | (0.00) | (0.00) | |||||
Weighted average number of shares outstanding | 3,111,169,896 | 1,354,502,045 | 2,729,928,072 | 1,354,502,045 |
See accompanying notes to the consolidated interim financial statements (unaudited).
4
VITANA-X INC. AND SUBSIDIARY
CONSOLIDATED INTERIM STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)
Nine months ended April 30, 2022 and 2021
(Unaudited)
Additional | Reserve for | Cumulative | Total | ||||||||||
Series A Preferred | Series B Preferred | Common Stock | Paid-in | Unissued | Treasury | Translation | Accumulated | Shareholders' | |||||
in USD | Notes Number | Amount | Number | Amount | Number | Amount | Capital | Shares | Stock | Adjustment | Deficit | Deficit | |
Balance at July 31, 2021 | - | - | 1,344,756 | 134 | 1,366,002,045 | 136,600 | 2,185,778 | 2,166,314 | - | (5,906) | (5,011,289) | (528,369) | |
Net loss for the interim period | - | - | - | - | - | - | - | - | - | - | (909,897) | (909,897) | |
Foreign currency translation | - | - | - | - | - | - | - | - | - | 6,017 | - | 6,017 | |
Total other comprehensive income | - | - | - | - | - | - | - | - | - | 6,017 | (909,897) | (903,880) | |
Issuance of Series A Preferred Stockfor previous period transactions
Issuance of Common Stock for conversion of notes
Exchange of Series B Preferred Stock for Common Stock
Cash received for the issuance of Common Stock
Common Stock granted for services
Settlement of convertible notes
5.3 | 1,000,000 | 100 | - | - | - | - | - | (100) | - | - | - | - | |||
5.1 | - | - | - | - | 817,593,471 | 81,759 | 2,149,644 | (2,231,403) | - | - | - | - | |||
5.1 | - | - | (1,344,756) | (134) | 887,555,197 | 88,756 | (88,622) | - | - | - | - | - | |||
5.1 | - | - | - | - | 59,038,999 | 5,904 | 311,551 | 226,675 | - | - | - | 544,130 | |||
5.1 | - | - | - | - | 45,290,000 | 4,529 | - | - | - | - | 102,841 | 107,370 | |||
4 | - | - | - | - | - | - | - | 200,905 | - | - | - | 200,905 |
Balance at January 31, 2022 | 1,000,000 | 100 | - | - | 3,175,479,712 | 317,548 | 4,558,351 | 362,391 | - | 111 | (5,818,345) | (579,844) | |
Net loss for the interim period | - | - | - | - | - | - | - | - | - | - | (159,384) | (159,384) | |
Foreign currency translation | - | - | - | - | - | - | - | - | - | 1,267 | - | 1,267 | |
Total other comprehensive income | - | - | - | - | - | - | - | - | - | 1,267 | (159,384) | (158,117) | |
Issuance of Common Stock for cash received in previous periods
Cash received for the issuance of Common Stock
5.1 | - | - | - | - | 67,864,330 | 6,787 | 323,702 | (330,489) | - | - | - | - | |||
5.1 | - | - | - | - | - | - | - | 11,000 | - | - | - | 11,000 |
Common Stock granted for services | 5.1 | - | - | - | - | 2,241,020 | 224 | - | - | - | - | 4,258 | 4,482 | |
Disposal of subsidiary | 8 | - | - | - | - | - | - | - | - | (257,600) | (1,378) | 707,332 | 448,354 | |
Balance at April 30, 2022 | 1,000,000 | 100 | - | - | 3,245,585,062 | 324,559 | 4,882,053 | 42,902 | (257,600) | - | (5,266,139) | (274,125) | ||
See accompanying notes to the consolidated interim financial statements (unaudited).
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Vitana-X Inc. published this content on 20 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 June 2022 13:13:11 UTC.
